Saneron CCEL Therapeutics Inc. is a biotechnology research company focused on neurological and cardiac cell therapy for the early intervention and treatment of several devastating or deadly diseases lacking adequate treatment options. The company's patented technology includes U-CORD-CELL from umbilical cord blood, which is a stem cell technology, as well as SERT-CELL from Sertoli cells. A University of South Florida spin-out, Saneron-CCEL Therapeutics is a subsidiary of CRYO-CELL International, Inc. In late 2001 the firm had merged with Saneron Therapeutics, Inc., to become Saneron CCEL Therapeutics, Inc. The company has been granted patents in many countries throughout the world for the therapeutic use of sertoli cells. With intellectual property for human cord blood as a source of stem cells, Saneron is committed to providing readily available, non-controversial, ethically acceptable cells, both stem cells and other cell types, for cellular therapies. Saneron has patented and patent-pending technology relating to our platform technology of: * U-CORD-CELLTM - Umbilical cord blood * SERT-CELLTM - Sertoli cells.
